PTHS Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 2.16
- P/S (TTM)
- 5.00
- EV/EBITDA
- -3.58
Profitability & growth
- ROE (TTM)
- -239.6%
- Operating margin
- -127.8%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 3.99
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
24 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Pelthos Therapeutics Inc.
Company profilePelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company is headquartered in Durham, North Carolina.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NYSE MKT
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 4020 STIRRUP CREEK DRIVE, DURHAM, NC
- Fiscal year end
- December
- Latest quarter
- Dec 31, 2025
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer